Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 04, 2021 16:15 ET
|
ARCA biopharma, Inc.
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement
July 07, 2021 08:00 ET
|
ARCA biopharma, Inc.
Provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma,...
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:15 ET
|
ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA...
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
March 18, 2021 16:30 ET
|
ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating...
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
December 15, 2020 08:30 ET
|
ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19
September 21, 2020 08:00 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
May 28, 2020 08:00 ET
|
ARCA biopharma, Inc.
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...
Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula
February 26, 2020 07:00 ET
|
Guardion Health Sciences, Inc.
Guardion® has signed a Letter of Appointment with Ho Wah Genting Berhad (HWGB) to create a new formula, designed to enhance the immune system.The formula will be a unique and exclusive brand of HWGB ...